Clinical Trial Update: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1]

View source ↗

Summary

XMT-1536, an investigational NaPi2b-targeting agent from Mersana Therapeutics, completed a first-in-human Phase 1 dose-escalation study in cancers likely to exp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• XMT-1536

Snippet

Sponsor: Mersana Therapeutics | Conditions: Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1 | Status: COMPLETED